Although further analysis is needed, the present study can support our hypothesis that BTG2/TIS21 is a promising target to treat metastatic cancers with high TWIST1 expression by employing inhibitors to relieve epigenetic silencing of BTG2, which can prevent cancer progression from DCIS to infiltrating carcinoma. Here, TWIST1 is linked to cancer.